Overview of Alese

Property	Description
Active ingredient	Allylestrenol (C21H32O)
Form	Oral tablet
Pharmacological class	Synthetic Progestogen (Progestin)
Common purpose	Pregnancy maintenance and support
Origin	Synthetic (Steroidal derivative)

Allylestrenol, recognized globally by its International Nonproprietary Name (INN), is a potent synthetic progestogen, a class of pharmaceutical agents engineered to mimic the functions of the natural hormone progesterone. It is classified by the World Health Organization (WHO) ATC system under G03DC01 (Estren derivatives), defining it as a highly specialized hormonal agent. The core purpose of Allylestrenol is to provide pregnancy maintenance and support, particularly by stabilizing the uterine environment during critical phases of gestation, a role pharmacologically recognized in obstetric care.

What Type of Medicine is Alese (Allylestrenol)?

Alese belongs to the high-level pharmacological category of progestins, which are synthetic compounds structurally similar to progesterone. As a steroidal small molecule, Allylestrenol is specifically derived from 19-nortestosterone, a chemical optimization that makes it an highly effective orally active progestogen. This synthetic structure is clinically confirmed to be superior to natural progesterone in terms of oral absorption and stability. Furthermore, Allylestrenol is widely reported to be a pure progestogen, meaning it specifically targets progesterone receptors without causing the significant androgenic or estrogenic cross-effects sometimes seen with other synthetic derivatives.

Composition, Origin, and Pharmaceutical Form

The composition of the medicine consists exclusively of the active ingredient, Allylestrenol (C21H32O), compounded as a single-ingredient product in a compressed oral tablet. This formulation provides a consistent and convenient route of administration. The drug's structure and activity as a progestogen agonist are well-defined in chemical databases. The synthetic structure is vital because it is highly stable, ensuring the patient receives a precise, quantifiable amount of the agent necessary for systemic hormonal support. The oral form is the standard delivery method for patients requiring sustained hormonal reinforcement during early gestation.

General Purpose: Support for Pregnancy

The primary function of Allylestrenol centers on stabilizing the conditions required for a successful pregnancy. This stability is achieved by the medicine’s core action of promoting uterine relaxation, which reduces undesirable activity and contractions of the myometrium. The drug is typically employed when a need for exogenous hormonal support is identified, reinforcing the progestational environment. Its biological activity also includes stimulating the syncytiotrophoblast, which is integral to the hormonal production required for sustaining the pregnancy.

What side effects are possible with Alese?

Possible Side Effects and Safety Information

The safety profile of Allylestrenol, a synthetic progestogen, is derived from official regulatory documentation, which classifies possible effects according to their frequency and the physiological system affected. The data reflect patterns observed during clinical use and mandatory safety signals.

Officially Documented Adverse Reactions

Adverse reactions are classified into observed frequency categories, with effects commonly reported and those considered rare, based on clinical experience.

Classification	System-Organ Class	Examples of Documented Effects
Common	Nervous System, Gastrointestinal, General Disorders	Headache, Nausea, Dizziness, Fatigue, Breast Tenderness, Change in Weight, Bloating
Rare	Hepatobiliary Disorders, Respiratory System	Abnormal Liver Function, Decreased Lung Function

Serious safety signals documented in prescribing information, common to the progestogen class, include the theoretical risk of Thromboembolic Disorders (blood clots) and specific observations such as severe Visual Disturbances and signs of Severe Allergic Reactions.

Safety-Related Restrictions and Contraindications

The medicine is strictly contraindicated and should not be used in individuals with severe pre-existing conditions, including Severe Hepatic Impairment or known or suspected Hormone-Dependent Carcinomas (e.g., breast or uterine cancer). Other restrictions include cases of Cerebral Apoplexy, Undiagnosed Vaginal Bleeding, or known Hypersensitivity to the active ingredient. Additionally, use requires caution in patients with existing conditions like Renal Dysfunction or Heart Disease, and it is generally not recommended during breastfeeding or for children under 16 years of age.

Overdose and Emergency Response

The official regulatory guidance for an acute overdose of Allylestrenol (Alese) reflects a profile of low immediate clinical severity. Prescribing information confirms that following the ingestion of several tablets at once, there is generally no need for great concern, as the anticipated clinical manifestations are non-severe and transient.

The documented symptoms of overdosage are consistent with common, non-specific gastrointestinal complaints, primarily involving nausea and vomiting. No specific severe systemic effects or life-threatening outcomes, such as major neurological or cardiovascular changes, are explicitly listed in the official regulatory overdose documentation.

Mandated Help-Seeking Action
- Despite the low severity, the regulatory authority mandates a specific action: patients should consult your doctor (or physician) for necessary guidance after an acute overdosage event. This is the official required help-seeking trigger.

Overdose Classification Element	Regulatory Status as Documented
Substance Toxicity	Officially classified as Harmful if swallowed (H302) (Toxicological basis)
Specific Antidote	No specific antidote is officially documented or known to exist
Supportive Procedures	No specific procedural steps (e.g., gastric lavage, activated charcoal) are explicitly described in the regulatory guidance
Monitoring Requirements	No mandatory hospital monitoring or continuous observation rules are explicitly documented

Therapeutic Uses of Alese

Allylestrenol is a synthetic progestogen applied in obstetric care which is commonly used to help manage symptoms related to conditions presenting with systemic or localized discomfort.

This medication is generally applied in clinical settings that involve acute or unstable symptom patterns, which includes conditions such as threatened abortion, the recurrent pattern of habitual miscarriage, and situations requiring additional hormonal support for luteal phase defects or during Assisted Reproductive Techniques (ART). It is relevant when supportive symptom management is appropriate during symptomatic phases.

“This medicine is commonly used to help with symptoms related to heightened physiological activity, focusing on symptomatic manifestations of irritability.”

The medication is commonly used to help with symptoms like crampy pelvic pain, undesirable myometrial contractions, and vaginal bleeding associated with a threatened loss. This provides support that helps ease the overall symptom burden during episodes of increased discomfort, which may assist with maintaining functional stability.

Quick Fact: Relief for Uterine Symptoms

Allylestrenol may assist with managing symptoms that create noticeable physiological strain, and is relevant for easing the symptom cluster of uterine irritability. It supports patients during episodes of heightened discomfort and helps improve day-to-day comfort during symptomatic periods of early gestation.

Eligibility and Restrictions for Use

Alese (Allylestrenol) eligibility is strictly defined by its role as a progestogen for specific pregnancy support, according to official regulatory labeling. The medicine is primarily allowed for adult women of childbearing age who are pregnant and require treatment for threatened or habitual abortion.

Absolute Contraindications

Official regulatory documents formally prohibit use in patients with known severe hepatic impairment (severe liver disease) and those with a history of hormone-dependent carcinoma (e.g., breast or uterine cancer). Furthermore, individuals with a history of thromboembolic disorders or undiagnosed vaginal bleeding must not use the medicine.

Population Restrictions

Conditional restrictions apply to other patient groups. Use is not recommended for children under 16 years of age, as safety and effectiveness have not been established in the pediatric population. Use is also not recommended during lactation (breastfeeding) as the agent may transfer to the nursing infant. Regulators advise that the medicine be used with caution in patients with certain conditions, including renal dysfunction, heart disease, epilepsy, or chronic breathing disorders.

What should I know about interactions with other medicines?

Allylestrenol (Alese) has a distinct regulatory profile regarding co-administration with other substances. The official prescribing information is characterized by the absence of specific, mandated interaction restrictions across major categories.

Mandatory Interaction Restrictions

The official documentation does not cite specific drug-drug interactions that necessitate a formal contraindication for co-administration. Consequently, no medicinal products are explicitly designated in regulatory sources as strictly prohibited due to interaction risk.

The official profile does not include mandatory rules for the timing of administration, meaning no dose separation (e.g., "administer X hours apart") is required when Alese is taken alongside other medications.

Mechanistic and Exposure Information

Interaction studies that define specific restrictions based on metabolic pathways, such as those involving Cytochrome P450 (CYP) enzymes or drug transporters (P-gp), are not formally documented in the regulatory labeling. The official data does not mandate any dose adjustments for Alese or co-administered substances based on altered exposure (e.g., changes in AUC or Cmax) from drug interactions.

Food, Alcohol, and Herbal Products

Official regulatory information confirms that no specific constraints are defined for the co-administration of Alese with food, alcohol, or herbal products. The regulatory label includes no specific warnings or restrictions for these non-medicinal products.

Mechanism of Action

Progesterone Receptor Agonism

Allylestrenol primarily acts as an agonist at the Intracellular Progesterone Receptor (PR), a key mechanism of steroid hormone action. By binding to this receptor, the drug initiates a genomic cascade, modulating the transcription of genes necessary for supporting the uterine lining. This action promotes the secretory and decidual transformation of the endometrium, which mediates sustained endometrial tissue integrity.

‍️ Modulation of Uterine Muscle Excitability

The mechanism also involves a direct physiological effect on the smooth muscle of the uterus (myometrium). This is achieved by raising the threshold for muscle activation, partly through reducing the density and sensitivity of Oxytocin receptors. This modulation limits the intensity and frequency of myometrial contractions, resulting in reduced uterine smooth muscle excitability.

Placentotropic and Endocrine Support

Allylestrenol exerts a placentotropic effect—meaning it actively stimulates the syncytiotrophoblast tissue within the placenta. This stimulation increases the tissue's capacity to produce endogenous hormones, such as natural Progesterone. This positive feedback loop augments the progestational state by increasing systemic hormonal mediator levels beyond the initial exogenous input.

Dosage and Administration Information

Official Administration Guidelines

Alese (levonorgestrel and ethinyl estradiol tablets) is an oral medication that must be taken daily according to a strict 28-day regimen for the prevention of pregnancy.

Dosing Schedule and Route

Attribute	Instruction
Route of Administration	Oral
Active Tablet Dose	0.10 mg levonorgestrel and 0.02 mg ethinyl estradiol
Daily Frequency	One tablet must be taken every 24 hours (approximately the same time each day)
28-Day Regimen	Take 21 consecutive active tablets, followed by 7 consecutive inactive (non-hormonal) tablets
New Pack Start	A new 28-day pack must be started on the day immediately following the last tablet from the previous pack
With Food	May be taken with or without food

Starting the First Cycle

There are two primary methods for starting the first cycle of use, which must be chosen at the outset:

Day 1 Start: Begin taking the first active tablet on the first day of the menstrual period.
Sunday Start: Begin taking the first active tablet on the first Sunday after the menstrual period begins. If the period begins on a Sunday, the first tablet is taken that day.

Missed Dose Instructions

The required procedure for a missed dose is strictly dictated by the number and type of tablets missed:

Missed One Active Tablet: Take the missed active tablet as soon as it is remembered, even if this means taking two tablets in one day. Continue taking the rest of the pills in the pack on the scheduled day and time.
Missed Two or More Active Tablets (Weeks 1, 2, or 3): Refer to the specific instructions provided within the patient information leaflet, as this requires immediate procedural changes, including the use of a non-hormonal back-up method for 7 days.
Missed Inactive Tablet(s): Throw away the missed inactive tablet(s) and continue to take one tablet daily until the pack is empty. No back-up method is needed for inactive tablets.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Clinical research on Alese (levonorgestrel/ethinyl estradiol) primarily focused on evaluating its effectiveness in preventing pregnancy. Studies examined the potential of the drug in healthy women of reproductive age. In one large-scale, open-label trial, a Pearl Index of 0.3 was reported, representing one of the core measures used to assess contraceptive efficacy.

Research also investigated the pharmacokinetics, noting that the active ingredients, levonorgestrel and ethinyl estradiol, showed accumulation in the body after multiple doses over a typical 21-day regimen. These findings informed the understanding of the drug's absorption and metabolism profile.

Safety and Tolerability Profile

Clinical trials provided data on the safety profile by tracking adverse events. Observations in these studies included events such as nausea, headache, injection site reactions (in transdermal formulations), and upper respiratory tract infections.

In studies involving combined hormonal contraceptives, researchers noted that, while the majority of events were classified as mild, some patients experienced serious adverse events that required intervention, with some reports noting thromboembolic events in certain subpopulations. Long-term safety findings are often collected through post-market studies to further monitor the drug's profile over extended periods of use.

Frequently Asked Questions (FAQ)

Common questions about Alese (FAQ)

Q: What is the main reason Alese is prescribed?

The main indication for Alese, as stated in regulatory documents, is the prevention of pregnancy in females of reproductive potential. It works by using a combination of hormones to suppress ovulation and create changes in the cervical mucus and uterine lining.

Q: Is Alese used for things other than birth control?

While the primary purpose described in official labeling is contraception, the hormones in combination oral contraceptives may also be associated with other effects. These reported effects may include an association with more regular periods, potentially decreasing blood loss and painful periods.

Q: Why does Alese have two different hormones?

Alese is a combination product that includes two different types of hormones: a progestin (levonorgestrel) and an estrogen (ethinyl estradiol). This combination is used primarily for the suppression of ovulation and is considered an effective method of contraception. This dual hormonal action is a key component of the medicine’s mechanism.

Q: How quickly is Alese expected to start working?

Regulatory documents require the use of a non-hormonal back-up method of contraception, such as condoms, for the first 7 days of use after starting the medicine. This temporary measure is specified by regulatory guidelines to support contraceptive effectiveness during the initial period.

Q: How long does Alese stay in the system after stopping?

Official pharmacokinetics data describe how quickly the active hormones are eliminated from the body. The half-life of levonorgestrel is approximately 36 hours, and the half-life of ethinyl estradiol is approximately 18 hours. The half-life measures the time it takes for half of the substance to be removed from the bloodstream.

Q: Is it common to experience mood changes while on Alese?

Mood changes, including feelings of depression and nervousness, are listed in the adverse reactions reported in clinical use of combination oral contraceptives. These are categorized among the commonly reported side effects.

Q: Is there a link between Alese and changes in skin condition (like acne)?

Acne is reported as an adverse reaction by people taking this medication. Additionally, some official information describes a possibility of developing chloasma (patchy brown or dark brown discoloration of the skin), which may not fade entirely after stopping the drug.

Q: Do antibiotics reduce the effectiveness of Alese?

Regulatory documents warn that some medications can reduce the effectiveness of oral contraceptives. Regulatory guidance suggests that if a patient is taking certain antibiotics, additional non-hormonal contraception may be recommended in these cases.

Q: Can Alese affect the results of blood tests?

Official regulatory information states that the medicine may affect the results of some medical tests. These effects can apply to blood and urine tests, and healthcare providers should be aware of this possibility.

Q: Is Alese appropriate for women who are close to menopause?

Alese is indicated for females who are of reproductive potential. The official documentation states that the medicine is not indicated for use in postmenopausal or geriatric women.

Q: Can women with a history of migraines use Alese?

Official prescribing information lists migraines as a contraindication in certain cases. The drug is strictly contraindicated in women who experience migraines with aura (headaches with focal neurological symptoms). It is also contraindicated in women over the age of 35 who experience any type of migraine headache.

Q: What are the inactive ingredients listed in Alese pills?

The full list of inactive ingredients is typically provided in the product description section of the regulatory label. These substances help form the tablet and commonly include ingredients such as lactose monohydrate, magnesium stearate, and polacrilin potassium.

Q: Does Alese come in different strengths?

The Alese brand is generally associated with one specific strength of its active hormonal ingredients: 0.10 mg levonorgestrel and 0.02 mg ethinyl estradiol. This consistent dosage defines it as a low-dose pill.

Q: What is the typical duration of use for Alese?

Alese is indicated for use for the prevention of pregnancy in women who choose this method of contraception. Regulatory documents do not specify a maximum duration, indicating it is intended for continuous, long-term use across the reproductive years.

Q: Is breakthrough bleeding a common occurrence when starting Alese?

Yes, official safety information indicates that vaginal bleeding between periods, known as spotting or breakthrough bleeding, is a common occurrence. This side effect is most frequently reported during the first few months of use.

Q: What should be clarified if I am taking seizure medication and starting Alese?

Regulatory documents caution that certain anticonvulsant drugs (medications used to treat seizures) can interact with oral contraceptives. This interaction may potentially reduce the effectiveness of Alese, necessitating clarification with a healthcare professional regarding appropriate contraceptive precautions.

Q: Are there specific safety warnings related to Alese and smoking?

Yes, the official prescribing information includes a Boxed Warning regarding smoking. Combination oral contraceptives are strictly contraindicated (official medical term for should not be used) in women over the age of 35 who smoke, as this combination significantly increases the risk of serious cardiovascular events.

Q: Can Alese be used by women who have never had children?

Alese is indicated for use by females of reproductive potential. There are no restrictions in the official product information that preclude use by women who have not previously had children.

Q: What is the expected experience when stopping Alese?

Upon discontinuing the medication, regulatory documents note that changes in the menstrual cycle may be expected. This can include the return of previous cycle characteristics, or the cessation of reported side effects, such as a return of acne or pre-existing symptoms.

Q: Is it normal to have lighter periods while taking Alese?

Yes, oral contraceptives can sometimes lead to changes in the menstrual cycle. This can include periods that are more regular or a decrease in the amount of blood loss, as described in clinical experience.

Q: Does Alese protect against sexually transmitted infections?

No. Regulatory information explicitly warns that oral contraceptives, including Alese, do not protect against HIV/AIDS or other sexually transmitted diseases (STDs). A separate barrier method, such as a condom, is generally recommended for protection against STDs.

Q: Is there a generic version of Alese available?

Yes, the drug is available under the generic name levonorgestrel and ethinyl estradiol tablets. This generic combination is also available under several other brand names for the same dose.

Q: Why is folic acid sometimes mentioned in relation to Alese?

Folic acid is sometimes mentioned because it is included as a component in certain specific product kit versions of levonorgestrel and ethinyl estradiol formulations. This addition is noted in the product descriptions of those specific kits.

Q: Can vomiting or diarrhea affect how well Alese works?

Gastrointestinal issues like vomiting and diarrhea are reported as side effects. If vomiting occurs shortly after taking an active tablet, the absorption of the medicine may be compromised. In this case, specific instructions for a missed dose may be applicable.

Q: Do any official documents describe Alese as affecting blood sugar levels?

Official regulatory documents list diabetes mellitus with certain vascular complications as a contraindication. Additionally, blood and urine tests may be required to monitor for unwanted effects, which can include effects on blood sugar.

Q: Can Alese be used immediately after childbirth?

Official documentation advises that patients should inform their healthcare provider if they had given birth within 4 weeks before starting this medication. Official guidance suggests use may need to be assessed after childbirth based on a careful assessment of individual factors.

Q: How is Alese expected to influence the menstrual cycle?

The medicine is designed to create a scheduled withdrawal bleed (period) during the days the inactive tablets are taken. Additionally, the official label and clinical experience indicate that the pill may lead to more regular periods, less blood loss, and decreased painful periods.

Q: What is the difference in hormone dose between Alese and a high-dose pill?

Alese is designated as a low-dose oral contraceptive, containing 20 mu g of ethinyl estradiol. High-dose oral contraceptives, which are less common today, historically contained 30 mu g, 35 mu g, or more of ethinyl estradiol.

Q: What are the typical non-contraceptive benefits people report for Alese?

Beyond preventing pregnancy, combination oral contraceptives may be associated with other non-contraceptive effects. These include making periods more regular, and potentially decreasing blood loss and the pain associated with menstruation.

Q: Is Alese considered a monophasic or triphasic pill?

Alese is classified as a monophasic combination oral contraceptive pill (COC). This classification means that the active tablets taken throughout the first three weeks of the cycle all contain the same, fixed dose of hormones. This structure is defined in the official product information for the drug.

Q: Is Alese considered a low-dose birth control pill?

Yes, according to the official product information, Alese is classified as a low-dose oral contraceptive. This designation is based on the amount of estrogen (ethinyl estradiol) it contains. Older or high-dose oral contraceptives typically contain higher levels of estrogen.

How should Alese be stored and disposed of?

How to Store and Dispose of Alese (Levonorgestrel and Ethinyl Estradiol Tablets)

Official regulatory guidelines define specific conditions for storing and disposing of Alese to maintain its stability and ensure safety.

Storage Requirements

Alese tablets must be stored at Controlled Room Temperature, which is between 20 C and 25 C (68 F and 77 F). The product must be protected by keeping it away from excess heat, moisture, and direct light, and it must be kept from freezing. The medication should always be stored out of the reach of children.

Disposal Instructions

Expired or unused Alese must be disposed of properly. The recommended method is to utilize a community drug take-back program or an authorized collector. If these are unavailable, follow the official guidance for household disposal, which involves mixing the tablets with an undesirable substance before sealing and placing in the trash. The tablets should not be flushed down the toilet.

Alese